Inbrija (levodopa) NDC 0259-6142

NDC codes

FDA NDC Directory

Product NDC (as listed)0259-6142Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00259-6142Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
0259-6142-16	00259614216	4 BLISTER PACK in 1 CARTON (0259-6142-16) / 4 CAPSULE in 1 BLISTER PACK (0259-6142-01)Marketed from Dec 22, 2018 · Sample package
0259-6142-32	00259614232	8 BLISTER PACK in 1 CARTON (0259-6142-32) / 4 CAPSULE in 1 BLISTER PACK (0259-6142-01)Marketed from Dec 22, 2018 · Sample package
0259-6142-60	00259614260	15 BLISTER PACK in 1 CARTON (0259-6142-60) / 4 CAPSULE in 1 BLISTER PACK (0259-6142-01)Marketed from Dec 22, 2018

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Inbrija
Generic name (nonproprietary): levodopa
Active ingredients: Levodopa — 42 mg/1
Dosage form: Capsule
Route: Respiratory (Inhalation)
Labeler: Merz Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 209184
Marketing start: Dec 22, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Aromatic (Chemical structure)
Identifiers: Product ID 0259-6142_ec522c79-6f5a-41f8-b3b1-78159a36f3b6SPL ID ec522c79-6f5a-41f8-b3b1-78159a36f3b6SPL set ID 077c0f39-a3a2-4b2b-a184-09131889dcfbRxCUI 2107616, 2107621UNII 46627O600J
Pharmacologic class: Aromatic Amino Acid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N400259614216 followed by a unit qualifier and the quantity

Package 00259-6142-16. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 20, 2026.

Indications (excerpt from the label)

INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is an aromatic amino acid indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 209184

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 209184
Product	Strength	Form · route	Labeler	Product NDC
Inbrijalevodopa	Levodopa 42 mg/1	CapsuleRespiratory (Inhalation)	Merz Pharmaceuticals, LLC	10144-342